Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-31
2011-05-31
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07951950
ABSTRACT:
Disclosed are CRTH2 inhibitors represented by Structural Formula (I):The values for the variables of Structural Formula (I) are provided herein.
REFERENCES:
patent: 5258510 (1993-11-01), Ogawa et al.
patent: 6048873 (2000-04-01), Vasudevan et al.
patent: 6147089 (2000-11-01), DeNinno et al.
patent: 6197786 (2001-03-01), DeNinno et al.
patent: 6291677 (2001-09-01), Vasudevan et al.
patent: 6310075 (2001-10-01), DeNinno et al.
patent: 6313107 (2001-11-01), Vasudevan et al.
patent: 6313142 (2001-11-01), Damon et al.
patent: 6362198 (2002-03-01), Goldstein et al.
patent: 6362199 (2002-03-01), Di Fabio
patent: 6395751 (2002-05-01), DeNinno et al.
patent: 6489478 (2002-12-01), DeNinno et al.
patent: 6586448 (2003-07-01), DeNinno et al.
patent: 6600045 (2003-07-01), Damon et al.
patent: 7211672 (2007-05-01), Ghosh et al.
patent: 7504508 (2009-03-01), Ghosh et al.
patent: 2002/0022218 (2002-02-01), Li et al.
patent: 0987251 (2000-03-01), None
patent: 0992496 (2000-04-01), None
patent: 1125929 (2001-08-01), None
patent: 1221439 (2002-07-01), None
patent: 1413306 (2004-04-01), None
patent: P200253557 (2002-02-01), None
patent: WO 9105549 (1991-05-01), None
patent: WO 9401113 (1994-01-01), None
patent: WO 0006153 (2000-02-01), None
patent: WO 0017165 (2000-03-01), None
patent: WO 0017166 (2000-03-01), None
patent: WO 0140190 (2001-06-01), None
patent: WO 0149675 (2001-07-01), None
patent: WO 0158875 (2001-08-01), None
patent: WO 0176629 (2001-10-01), None
patent: WO 0211710 (2002-02-01), None
patent: WO 0218361 (2002-03-01), None
patent: WO 0222585 (2002-03-01), None
patent: WO 02058652 (2002-08-01), None
patent: WO 02079165 (2002-10-01), None
patent: WO 02088069 (2002-11-01), None
patent: WO 03097042 (2003-11-01), None
patent: WO 03097598 (2003-11-01), None
patent: WO 03105849 (2003-12-01), None
patent: WO 2004032848 (2004-04-01), None
patent: WO 2004035543 (2004-04-01), None
patent: WO 2004052863 (2004-06-01), None
patent: 2004/085401 (2004-10-01), None
patent: WO 2005007094 (2005-01-01), None
patent: WO 2005/100321 (2005-10-01), None
Fugi, abstract only CA 117:58764, abstract nly of JP 03239246, 1991.
Zalukaev, L.P., et al., “Bimolecular alkylidenearylamines. XI. New data on intermolecular donor-acceptor reactions in 4-anilino-2-methyl-1,2,3,4-tetrahydroquinolines,”Chemical Abstracts, Accession No. 67:53250 (1967).
Zalukaev, L.P., et al., “Bimolecular alkylidene aryl amines. X. Intramolecular donor-acceptor interaction in 2-methyl-4-anilino-1,2,3,4-tetra-hydroquinoline,”Chemical Abstracts, Accession No. 65:81601 (1966).
Funabashi, Masuo, et al., “Configuration and conformation of so-called bis(alkylidenearlyamines),”Chemical Abstracts, Accession No. 72:31075 (1969).
Zalukajevs, L., “Bimolecular alkylidenearylamines. II. Structure of the products of bromination of 1-benzoyl-2-methyl-4-anilino-1,2,3,4-tetrahydroquinoline,”Chemical Abstracts, Accession No. 48:56687 (1951).
Zalukajevs, L., et al., “Bimolecular alkylidenearylamines. IX. Steric structure of 2-methy1-4-anilino-1,2,3,4-tetrahydroquinolines,”Chemical Abstracts, Accession No. 62:22149 (1964).
Zalukajevs, L., et al., “Bimolecular alkylidenearylamines. VIII. Synthesis and bromination of 2-methyl-4-N-acetylanilino-1,2,3,4-tetrahydroquinoline,”Chemical Abstracts, Accession No. 59:54789 (1963).
International Search Report dated Jun. 7, 2006 from PCT/US06/006287, which corresponds to U.S. Appl. No. 11/360,885, 2006.
Carson Kenneth G.
Elder Amy M.
Ghosh Shomir
Harrison Sean
Little Jeremy D.
Millennium Pharmaceuticals Inc.
Seaman D. Margaret
LandOfFree
PGD2 receptor antagonists for the treatment of inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PGD2 receptor antagonists for the treatment of inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PGD2 receptor antagonists for the treatment of inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684412